Press Releases

    • OCT 06 2015

    Oncoceutics Closes Series A Financing for First-in-Class Cancer Drug

    Hummelstown, PA (October 6, 2015) – Oncoceutics announced the closing of a Series A financing round, led by Spring Mountain Capital, LP, with participation by additional private investors.  The company will use the proceeds of the financing in conjunction with non-dilutive grant awards, public-private partnerships and academic alliances to continue the development of its lead

    • SEP 01 2015

    Oncoceutics Awarded Grant for Phase II Brain Cancer Trial

    Hummelstown, PA (September 1, 2015) – Oncoceutics announced that it has been awarded the second part of a Fast-Track Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) to clinically evaluate its lead molecule, ONC201, in advanced brain cancer (glioblastoma multiforme or GBM).  The company previously received the first part of the

    • AUG 25 2015

    Enrollment Begins In Expansion Phase of ONC201 Clinical Trial

    Hummelstown, PA (August 25, 2015) –– Oncoceutics, Inc. announced that the first patients have been enrolled in the expansion phase of the first-in-man clinical trial with ONC201 at the Rutgers Cancer Institute of New Jersey (CINJ). Previously, Oncoceutics reported the completion of the dose escalation portion of the trial entitled “Oral ONC201 in Treating Patients

    • AUG 11 2015

    Analog of ONC201 Selected as Clinical Development Candidate

    Hummelstown, PA (August 11, 2015) – Oncoceutics, Inc. announced the selection of ONC212 to be the first development candidate from its portfolio of analogs derived from its lead compound ONC201. The decision to advance this analog follows the recent completion of a Phase I dose escalation study of ONC201 in patients with various treatment-refractory solid tumors